Sydney, Aus — Frost & Sullivan today released its latest white paper, ‘Asia: Preferred Destination for Clinical Trials’, with Asia Pacific specialist CRO Novotech. Research from the new white paper revealed Asia is quickly becoming a clinical research powerhouse; facilitated by the availability of vast treatment-naive patient pools, exceptional clinical infrastructure and talent, and low operational costs.
Commenting on the white paper, Novotech CEO Dr. John Moller said “Asia is an increasingly attractive destination for our biotech clients. The huge patient pools available in Asia are mainly concentrated in easily accessible urban areas, meaning that trials tend to recruit faster. In addition, the cost of trials in most Asian countries is significantly lower than the West.”
“Now is an exciting time for clinical trials taking place in Asia. There are a number of large, state-of-the-art clinical trial centers in Asia that meet patient enrolment and retention goals, generate high-quality data, and are led by globally recognised key opinion leaders. Regulatory processes in Asia are continuing to become more streamlined. Novotech is actively working with a number of regulatory authorities and clinical trial centres to improve approval processes and timelines,” said Dr. Moller.
Novotech presented the white paper to an audience of senior biotechnology and pharmaceutical executives in a private event at Outsourcing Clinical Trials – West Coast 2017, held in Burlingame, California (USA).
The new Frost & Sullivan White Paper, ‘Asia: Preferred Destination for Clinical Trials’, is available as Executive Summary (http://bit.ly/2lkrhAB) or Full White Paper (http://bit.ly/2mkqHmn).